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dard treatment, including ASA, in patients with acute
coronary syndromes without ST-elevation.
PCV64
COST-EFFECTIVENESS ANALYSIS OF
CORONARY REVASCULARISATION
TECHNIQUES AVAILABLE FOR THE TREATMENT
OF ISCHAEMIC HEART DISEASE
Magaz S1, Badia X2, Annemans L3, Lamotte M4
1Health Outcomes Policy And Economics, Barcelona, Spain;
2Health Outcomes Research Europe Group, Barcelona, Spain;
3Ghent University, HEDM, Meise, NA, Belgium; 4Health
Economics Disease Management (HEDM), Meise, Belgium
OBJECTIVES: To analyse the efﬁciency of the use of a
percutaneous transluminal coronary angioplasty (PTCA),
a coronary artery bypass graft (CABG), a conventional
Stent or a sirolimus-eluting Stent (Cypher) in the treat-
ment of Ischaemic Heart Disease (IHD) by means of a
cost-effectiveness analysis. METHODS: An international
decision analytical model was adapted to the Spanish
National Health System perspective in a time horizon of
1 year for 4 different populations of general patients with
IHD according to the type of vessel or lesion (one or 
multiple, small vessel—less that 3mm diameter, or long
lesion—more than 18mm long). The primary outcome of
the model was the cost per revascularisation avoided with
each technique when compared to a conventional Stent
(in the multiple lesions model the PTCA has not been 
considered as a relevant option). Incidence rates of re-
vacularisation for each subgroup were obtained from
published clinical trials and epidemiological studies.
Resource use data was determined by an expert panel.
Unit costs of the resources were extracted from local data-
bases and were expressed in Euros of 2002. RESULTS:
The PTCA has the lowest efﬁcacy with revascularisation
rates ranging from 19% to 28%) whilst the sirolimus
eluting-Stent is the most efﬁcacious option (rates ranging
from 1% to 4%. The less costly option is PTCA and the
most expensive in all types of patients is the CABG. Cost
per revascularisation avoided ranges between €1,042 of a
PTCA in small vessel patients to €56,035 with CABG in
patients with lesions in normal vessels. Cypher is a cost-
effective option in patients with normal vessels and long
lesions and becomes dominant in the multiple lesions
model. CONCLUSIONS: Drug eluting Stents have
proven efﬁcacy rates that have no precedents in the
history of IHD, reducing the incidence of revascularisa-
tion induced by restenosis and thus resulting in efﬁcient
options in most types of patients.
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OBJECTIVES: To quantify the economic value of the
sirolimus-eluting stent (SES) in treating acute coronary
heart disease, and to assist in determining its adequate
reimbursement price under the mandatory national health
insurance system in Korea. METHODS: A decision-
analytic model was used to investigate the incremental
cost-effectiveness of SES versus conventional stenting
(CS). Probabilities for clinical events were obtained from
the results of large, randomized, controlled clinical trials.
Types of costs included in the analysis were initial proce-
dure and hospitalization costs, and follow-up direct
medical costs for 5 years consisting of routine follow-up
treatments, adverse reactions, revascularization and death
costs. Cost information was obtained from administrative
data for 449 patients receiving CS in June 2002 from 5
Korean hospitals participating in this study. Since the
major clinical advantage of SES over CS is the reduction
of revascularization rates, we evaluated economic value
of SES in relation to direct medical costs of revascular-
ization. According to the customary notion in Korea, the
reimbursement price was deﬁned as the price of SES that
made the incremental cost-effectiveness ratio equal to the
cost of a revascularization itself. RESULTS: The esti-
mated reimbursement price for SES was US$3344 using
a discount rate of 5%. Based on this price, the national
ﬁnancial impact of replacing CS with SES by 10% was
estimated as extra spending of $0.96 million a year, 0.6%
increase in total national spending in treating coronary
artery disease in Korea. CONCLUSIONS: Analysis on 
the economic value of SES based on Korean cost struc-
ture of coronary artery disease provided objective stan-
dard for pricing decision and reimbursement strategy in
Korea.
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OBJECTIVE: A recently published analysis on the use 
of Cholesterol-Synthesis-Enzyme-Antagonists (CSEA) in
Germany stated that with the investment of nearly €1
billion; 87% of all possible €2.8 million. patients can be
treated sufﬁciently (Klose and Schwabe 2003). The aim
of the presented study is to show the cost-efﬁcacy as expe-
rienced by ofﬁce based physicians of the CSEA treatment.
METHODS: A cost-efﬁcacy-analysis was conducted on
base of the following data: Eight local experts (general
practitioners, cardiologists) out of a rural as well as an
urban setting assessed in a Delphi-Panel their practical
experience of reaching a deﬁned LDL-Cholesterol (LDL-
C) target according to European treatment guidelines
treating a patient with a predeﬁned risk with CSEA. Total
sales of CSEA in 2002 as stated by IMS (Institute for
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Medical Statistics) and actual drug prices (Rote Liste,
2003) were used to calculate total costs of CSA treatment
in Germany from the German payers perspective for the
year 2003. (Discounts from the whole saler, pharmaceu-
tical industry, retail pharmacies and patients copayments
were taken into consideration). RESULTS: Total efﬁcacy
as stated by the physicians depends on CSEA and was
seen between 53% and 76%. The total efﬁcacy experi-
enced by the physicians weighted with 2002 sales was
71%. Total sales in 2003 are €995.6 million. In total €1.4
billion must be invested for completely (100%) reaching
the LDL-C goal of the European treatment guideline.
CONCLUSION: Although it is stated by Klose and
Schwabe (2003) that nearly €2.million of estimated €2.8
million patients could be treated sufﬁciently with CSEA
the results of our study indicate that the investment for a
sufﬁcient treatment must be higher or the treatment itself
must be improved by more efﬁcient drugs.
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OBJECTIVES: To evaluate the total treatment cost 
and cost-effectiveness of three alternative treatments for
patients with acute myocardial infarction from the per-
spective of the Greek NHS. METHODS: A systematic
review of the literature was conducted to identify RCTs
evaluating the treatments considered. Outcomes include
all major health events associated with an AMI. Trial data
we extracted and used to populate a decision analytic
model. Data from long term studies were used to extrap-
olate 30-day and one-year data to end of lifetime. The
model also accounts for patient risk croup, in regards to
age, sex, time-to- treatment, etc. The database of a large
University Hospital was analyzed to estimate in-patient
and outpatient costs associated with various groups of
patients. Simulation was used to test the robustness of the
results. RESULTS: Outcome data primarily come from
GUSTO III and ASSENT 2 and their follow ups. For the
average patient life time costs on alteplase, reteplase 
and tenecteplase were similar, at €24,205, €24,308, and
€24,488 respectively. Average survival was 8.2221,
8.2110, and 8.2919 years respectively. Tenecteplase has
marginally higher cost and outcomes. Alteplase and ten-
ecteplase dominate the second arm and the incremental-
cost-per-life-year-saved of tenecteplase over alteplase is
about €4000, and for that reason it should be preferred
on the basis of its very cost-effective ratio. These results
are based the point estimates and in general terms they
also hold true when simulation is employed. CONCLU-
SIONS: The cost of the original treatment is only a minor
component of the total life time treatment cost of AMI
patients. The treatments evaluated here have similar sur-
vival and different health event proﬁles, but despite that
they are characterized by similar total treatment costs, so
that it is difﬁcult to distinguish between them. If anything,
tenecteplase is characterized by a marginally better cost-
effectiveness ratio.
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OBJECTIVES: Statin therapy reduces the rate of coro-
nary heart disease (CHD), but high costs in combination
with a large population eligible for treatment ask for pri-
oritizing. One of the tools of priority setting is cost-
effectiveness analysis (CEA). Even though all trials agree
on the size of the beneﬁt, CEA of statins report contra-
dictory results. We reviewed CEA comparing statins with
no pharmacological therapy and sought to synthesize cost
effectiveness ratios (CER) for categories of risk of CHD
and age. The level of heterogeneity among CER and its
potential sources were evaluated. METHODS: Systematic
review of the published statin CEA in Medline, the British
National Health Service Economic Evaluation database
and authors’ reference lists. Outcomes were standardized
by inﬂation and currency and stratiﬁed by risk and age.
CER under US$20,000 per life year saved were “cheap”,
over US$40,000 were “expensive” and in between were
“moderate”. Sources of heterogeneity in the outcomes
after stratiﬁcation were analyzed using a regression
model. RESULTS: Twenty-four studies were included,
yielding 216 CER. The range of CER varied 10-fold
(savings to $489,394). Disagreement existed at levels of
risk lower than 4%. After adjusting for risk in the regres-
sion model, the only signiﬁcant variable was funding
source. CONCLUSIONS: Statin therapy is cheap for high
levels of risk, but discrepancies exist at lower levels.
Scarce evidence exists for younger and older ages (<45,
>65). Competing interests between pharmaceutical com-
panies wanting to sell more and governments wanting to
spend less may have strong impact on the results. Clear
guidelines for CEA could reduce their vulnerability to bias
and assure reproducibility.
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